Effect of Preoperative Stellate Ganglion Block on Postoperative Atrial Fibrillation After Coronary Artery Bypass Grafting

December 8, 2025 updated by: Chong Lei, MD & phD, Xijing Hospital

Preoperative Stellate Ganglion Block Reduce the Incidence of Postoperative Atrial Fibrillation After Coronary Artery Bypass Grafting: A Prospective, Randomized Controlled Pilot Trial

The primary objective of this study is to determine the feasibility of preoperative stellate ganglion block in reducing the incidence of postoperative atrial fibrillation in patients undergoing CABG.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

60

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • China
    • Shaanxi
      • Xi'an, Shaanxi, China, 710032
        • Recruiting
        • Xijing Hospital
        • Contact:
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • more than 18 years old
  • undergoing CABG
  • Provide informed consent

Exclusion Criteria:

  • History of prior cardiac surgery or atrial fibrillation ablation;
  • Emergency coronary artery bypass grafting (CABG);
  • Concomitant cardiac procedures (e.g., congenital heart disease repair, left ventricular reconstruction, valve surgery, or aortic surgery);
  • Critical preoperative status requiring mechanical or pharmacological support before CABG;
  • Left ventricular ejection fraction (LVEF) <35%;
  • History of atrial fibrillation (defined as a supraventricular tachyarrhythmia characterized by rapid and irregular atrial electrical activity);
  • Significant mitral valve disease (mitral valve area <1.5 cm² or regurgitant jet area <4 cm²), significant aortic valve disease (valve area <1.5 cm² or regurgitant jet-to-left ventricular outflow tract ratio >25%);
  • Severe left atrial enlargement (left atrial anteroposterior diameter >55 mm);
  • Poorly controlled hyperthyroidism;
  • Conditions requiring radiotherapy, chemotherapy, or long-term hormonal therapy;
  • Patients with known clinical contraindications to stellate ganglion block (SGB).

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
No Intervention: Control group（C group）
the best available treatment without block (usual care)
Other: Stellate Ganglion Block（S group）
Ultrasound-guided stellate ganglion block with ropivacaine
Procedure: Stellate Ganglion Block
Ultrasound-guided stellate ganglion block with ropivacaine

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
postoperative atrial fibrillation（POAF）
Time Frame: within 7 days postoperatively
within 7 days postoperatively

Secondary Outcome Measures

Outcome Measure
Time Frame
cumulative time spent in postoperative atrial fibrillation
Time Frame: within 7 days postoperatively
within 7 days postoperatively
the need for antiarrhythmic medications to treat postoperative atrial fibrillation
Time Frame: within 7 days postoperatively
within 7 days postoperatively
the need for systemic anticoagulation due to postoperative atrial fibrillation
Time Frame: within 7 days postoperatively
within 7 days postoperatively
the need for postoperative electrical cardioversion
Time Frame: within 7 days postoperatively
within 7 days postoperatively
the duration of postoperative in-hospital stay
Time Frame: duration of postoperative hospital stay
duration of postoperative hospital stay
number of POAF
Time Frame: within 7 days postoperatively
within 7 days postoperatively

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Xijing Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 19, 2025

Primary Completion (Estimated)

May 31, 2026

Study Completion (Estimated)

July 31, 2026

Study Registration Dates

First Submitted

November 26, 2025

First Submitted That Met QC Criteria

December 8, 2025

First Posted (Estimated)

December 9, 2025

Study Record Updates

Last Update Posted (Estimated)

December 9, 2025

Last Update Submitted That Met QC Criteria

December 8, 2025

Last Verified

December 1, 2025

More Information

Terms related to this study

Other Study ID Numbers

  • KY20250716

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Adult Patients Undergoing CABG

Clinical Trials on Stellate Ganglion Block

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Slovakia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe